Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Evaluating adverse events after T-cell redirecting therapies in prostate cancer

Kevin Zarrabi • 29 May 2026
ASCO 2026
Genitourinary Cancer Prostate Cancer Antibodies CAR-T

Kevin Zarrabi, MD, MS, FACP, Thomas Jefferson University, Philadelphia, PA, shares insight into a meta-analysis analyzing the toxicity profiles of nearly 900 patients treated with T-cell redirecting therapies in prostate cancer. The toxicity profiles are consistent with those seen in other disease settings, with most cytokine release syndrome (CRS) events being grade 1 and 2. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kevin Zarrabi

Evaluating the current data for CDK4/6 inhibition in resistant prostate cancer
0:47
Evaluating the current data for CDK4/6 inhibition in resistant prostate cancer
Kevin Zarrabi • 29 May 2026
RiboX: enzalutamide with or without ribociclib in RB-positive mCRPC
2:18
RiboX: enzalutamide with or without ribociclib in RB-positive mCRPC
Kevin Zarrabi • 29 May 2026
Advances in T-cell redirecting therapies for prostate cancer
0:53
Advances in T-cell redirecting therapies for prostate cancer
Kevin Zarrabi • 24 Apr 2026
Combining 177Lu-PSMA-617 with T-cell engagers in prostate cancer
0:41
Combining 177Lu-PSMA-617 with T-cell engagers in prostate cancer
Kevin Zarrabi • 24 Apr 2026

Related Videos

Emotional health burden and unmet support needs in kidney cancer
2:19
Emotional health burden and unmet support needs in kidney cancer
Eric Jonasch • 30 May 2026
Improving emotional health assessment in patients with kidney cancer
0:57
Improving emotional health assessment in patients with kidney cancer
Eric Jonasch • 30 May 2026
Background and rationale for the PROTEUS trial in HR LPC/LAPC
0:48
Background and rationale for the PROTEUS trial in HR LPC/LAPC
Mary-Ellen Taplin • 29 May 2026
Future directions in prostate cancer from the PROTEUS trial
1:08
Future directions in prostate cancer from the PROTEUS trial
Mary-Ellen Taplin • 29 May 2026
The content of VJOncology is intended for healthcare professionals